Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Epetraborole · AN-3365, GSK-2251052

Small molecule · developed by AN2 Therapeutics

Phase 2/3 Most advanced trial (none active)
ANTX Developer
1 Registered trials

What is Epetraborole?

Epetraborole (also known as AN-3365 and GSK-2251052) is a small molecule studied in Mycobacterium avium complex (MAC) lung disease, including treatment-refractory MAC lung disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AN-3365, GSK-2251052, AN2-501971
Drug type
Small molecule
Therapy area
Infectious disease, Respiratory
Developer
AN2 Therapeutics, Inc (ANTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
6MC93Z2DF9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05327803 Phase 2/3 MAC Lung Disease Terminated ANTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MAC Lung DiseaseTreatment Refractory MAC Lung Disease

More from AN2 Therapeutics

AN2-502998 Phase 1

Follow ANTX, the company behind Epetraborole

See ANTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.